Role of α-Blockers in Type III Prostatitis: A Systematic Review of the Literature

Journal of Urology

Volumn 177, Issue 1, 2007, Pages 25-30

  Mishra, Vibhash C ^a   Browne, John ^b   Emberton, Mark ^c  

^a WEXHAM PARK HOSPITAL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

Author keywords

adrenergic antagonists; pelvic pain; prostate; prostatitis; randomized controlled trials

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; TAMSULOSIN; TERAZOSIN;

ADULT; AGED; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EMBASE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDLINE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATITIS; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; HUMANS; MALE; PROSTATITIS;

EID: 33845331350     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.08.090     Document Type: Review

References (33)

1. Roberts R.O., Lieber M.M., Rhodes T., Girman C.J., Bostwick D.J., and Jacobsen S.J. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 51 (1998) 578
2. McNaughton-Collins M., Meigs J.B., Barry M.J., Walker C.E., Giovannucci E., and Kawachi I. Prevalence and correlates of prostatitis in Health Professionals Follow-up Study Cohort. J Urol 167 (2002) 1363
3. McNaughton-Collins M., Stafford R.S., O'Leary M.P., and Barry M.J. How common is prostatitis?. A national survey of physician visits. J Urol 159 (1998) 1224
4. Nickel J.C., Nigro M., Valiquette L., Anderson P., Patrick A., Mahoney J., et al. Diagnosis and treatment of prostatitis in Canada. Urology 52 (1998) 797
5. Lobel B., and Rodriguez A. Chronic prostatitis: what we know, what we do not know, and what we should do!. World J Urol 21 (2003) 57
6. Wenninger K., Heiman J.R., Rithman I., Berghuis J.P., and Berger B.E. Sickness impact on chronic nonbacterial prostatitis and its correlates. J Urol 155 (1996) 965
7. Krieger J.N., Nyberg Jr. L., and Nickel J.C. NIH consensus definition and classification of prostatitis. JAMA 282 (1999) 236
8. Litwin M.S., McNaughton-Collins M., Fowler Jr. F.J., Nickel J.C., Calhoun E.A., Pontari M.A., et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. J Urol 162 (1999) 369
9. Propert K.J., Alexander R.B., Nickel J.C., Kusek J.W., Litwin M.S., Landis J.R., et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology 59 (2002) 870
10. Caropreso D., and Moon T.D. α-Blockers: an effective treatment for prostatitis?. Curr Urol Rep 1 (2000) 148
11. 1-adrenoreceptor antagonists in lower urinary tract symptoms: Beyond benign prostatic hyperplasia. Urology 62 suppl (2003) 34
12. Schaeffer A.J. Editorial: emerging concepts in the management of prostatitis/chronic pelvic pain syndrome. J Urol 169 (2003) 597
13. Schaeffer A.J. Etiology and management of chronic pelvic pain syndrome in men. Urology 63 suppl (2004) 75
14. Schaeffer A.J., Weidner W., Barbalias G.A., Botto H., Johansen T.E.B., Hochreiter W.W., et al. Summary Consensus Statement: diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 2 suppl (2003) 1
15. Anderson R.U. Management of chronic prostatitis-chronic pelvic pain syndrome. Urol Clin North Am 29 (2002) 235
16. Barbalias G.A. Why alpha-blockers in prostatitis?. Eur Urol 2 suppl (2003) 27
17. Malloy B.J., Price D.T., Price R.R., Bienstock A.M., Dole M.K., Funk B.L., et al. Alpha 1-adrenergic receptor subtypes in human detrusor. J Urol 160 (1998) 937
18. 1-adrenoceptors. Br J Pharmacol 117 (1996) 962
19. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996) 1
20. Mehik A., Alas P., Nickel J., Sarpola A., and Helstrom P. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology 62 (2003) 425
21. Cheah P., Liong M., Yuen K., Teh C., Khor T., Yang J., et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized placebo controlled trial. J Urol 169 (2003) 592
22. Nickel J., Narayan P., McKay J., and Doyle C. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 171 (2004) 1594
23. Alexander R.B., Propert K.J., Schaeffer A.J., Landis J.R., Nickel J.C., O'Leary M.P., et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized double-blind trial. Ann Intern Med 141 (2004) 581
24. Sivkov A., Oshepkov V., Egorov A., and Pataki K. Terazosin in patients with chronic prostatitis. BJU Int 94 suppl (2004) 5
25. Batstone R.D., Lynch J., and Dobble A. A randomized-placebo controlled pilot study of tamsulosin, naproxen, and combination in category IIIA/IIIB chronic prostatitis/chronic pelvic pain syndrome. J Urol 173 suppl (2005) 30
26. Lacquaniti S., Destito A., Servello C., Candidi M.O., Weir J.M., Brisinda G., et al. Terazosine and tamsulosin in nonbacterial prostatitis: a randomized placebo-controlled study. Arch Ital Urol Androl 71 (1999) 283
27. Gul O., Eroglu M., and Ozok U. Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. Int Urol Nephrol 32 (2001) 433
28. Evliyaoglu Y., and Burgut R. Lower urinary tract symptoms, pain and quality of life assessment in chronic nonbacterial prostatitis patients treated with α-blocking agent doxazosin; versus placebo. Int Urol Nephrol 34 (2002) 351
29. Lu M., Zhao S.T., Wang S.M., Shi B.K., Fan Y.D., and Wang J.Z. Alpha-blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH-IIIa): a prospective, placebo-controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi 25 (2004) 169
30. Argyropoulos A., Papadopoulos G., Liapis D., Polyzois K., Liakatas I., Fragoulis A., et al. The use of alfuzosin for the treatment of chronic prostatitis/chronic pelvic pain syndrome: is there a role for α-blockers?. Eur Urol 3 suppl (2004) 204
31. Tripp D.A., Nickel J.C., Landis J.R., Wang Y.L., Knauss J.S., and CPCKN Study Group. Predictors of quality of life and pain in chronic prostatitis/chronic pelvic pain syndrome: findings from the National Institutes of Health Chronic Prostatitis Cohort Study. BJU Int 94 (2004) 1279
32. Cheah P.Y., Liong M.L., Yuen K.H., Teh C.L., Khor T., Yang J.R., et al. Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology 64 (2004) 881
33. Nickel J.C., Pontari M., Moon T., Gittelman M., Malek G., Farrington J., et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol 169 (2003) 1401